{
    "name": "lucinactant",
    "comment": "Rx",
    "other_names": [
        "Surfaxin"
    ],
    "classes": [
        "Lung Surfactants"
    ],
    "source": "https://reference.medscape.com/drug/surfaxin-lucinactant-999727",
    "pregnancy": null,
    "lactation": null,
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [
                "For intratracheal use only",
                "Frequent clinical assessments for acute changes in lung compliance required; modify oxygen and ventilatory support to respond to changes in respiratory status",
                "During administration, if bradycardia, oxygen desaturation, endotracheal tube (ETT) reflux, or airway/ETT obstruction occurs, administration should be interrupted and the infantâ€™s clinical condition assessed and stabilized; ETT suctioning or reintubation may be required if airway obstruction persists or is severe",
                "Not indicated for use in adults for acute respiratory distress syndrome (ARDS); adults with ARDS who received lucinactant via segmental bronchoscopic lavage had an increased incidence of death, multi-organ failure, sepsis, anoxic encephalopathy, renal failure, hypoxia, pneumothorax, hypotension, and pulmonary embolism"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "ETT refulx",
            "percent": "18"
        },
        {
            "name": "Pallor",
            "percent": "9"
        },
        {
            "name": "Dose interruption",
            "percent": "9"
        },
        {
            "name": "ETT obstruction",
            "percent": "6"
        }
    ]
}